You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 39 No. 4, April 1982 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (575)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Tardive Dyskinesia

Prevalence and Risk Factors, 1959 to 1979

John M. Kane, MD; James M. Smith, PhD

Arch Gen Psychiatry. 1982;39(4):473-481.


Abstract



• Fifty-six prevalence surveys of tardive dyskinesia (TD) in neuroleptic-treated patients are reviewed, yielding an average prevalence of 20% as compared with 5% prevalence of "spontaneous" dyskinesia in 19 samples of untreated individuals. Reported prevalence has increased during the past two decades and is not attributable simply to the more widespread use of rating scales. Controlled studies of a variety of risk factors are reviewed and suggest that advancing age and, to a lesser extent, female sex are the two variables most consistently associated with increased prevalence. There are relatively few data supporting the assumption that the risk of TD development continues to increase with increasing neuroleptic exposure, CNS dysfunction, or exposure to antiparkinsonism medication.



Author Affiliations



From Long Island Jewish-Hillside Medical Center, Glen Oaks, NY (Dr Kane), and Hudson River Psychiatric Center, Poughkeepsie, NY (Dr Smith).


Footnotes



Accepted for publication Sept 21, 1981.

Reprint requests to Long Island Jewish-Hillside Medical Center, Glen Oaks, NY 11004 (Dr Kane).

References 27, 29, 32, 34, 35, 38, 39, 41, 47, 49, 51, 52, 72, 73.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Spectrum of tardive syndromes: clinical recognition and management
Bhidayasiri and Boonyawairoj
Postgrad. Med. J. 2011;87:132-141.
ABSTRACT | FULL TEXT  

Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis
Koning et al.
Schizophr Bull 2010;36:723-731.
ABSTRACT | FULL TEXT  

Neurological Signs and Involuntary Movements in Schizophrenia: Intrinsic To and Informative on Systems Pathobiology
Whitty et al.
Schizophr Bull 2009;35:415-424.
ABSTRACT | FULL TEXT  

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young et al.
Br. J. Psychiatry 2009;194:40-48.
ABSTRACT | FULL TEXT  

The Role of Pharmacogenetics in Treating Central Nervous System Disorders
Patnaik et al.
Exp Biol Med 2008;233:1504-1509.
ABSTRACT | FULL TEXT  

Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
Kenney et al.
J Clin Pharmacol 2008;48:379-384.
FULL TEXT  

Drug-Induced Movement Disorders
Claxton et al.
Journal of Pharmacy Practice 2007;20:415-429.
ABSTRACT  

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
TOHEN et al.
Br. J. Psychiatry 2004;184:337-345.
ABSTRACT | FULL TEXT  

A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania
Tohen et al.
Arch Gen Psychiatry 2003;60:1218-1226.
ABSTRACT | FULL TEXT  

Pharmacogenomics in schizophrenia: the quest for individualized therapy
Basile et al.
Hum Mol Genet 2002;11:2517-2530.
ABSTRACT | FULL TEXT  

Use of antipsychotic drugs and lithium in mania
COOKSON
Br. J. Psychiatry 2001;178:s148-s156.
ABSTRACT | FULL TEXT  

Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos et al.
Arch Gen Psychiatry 1996;53:313-319.
ABSTRACT  

Duration of Neuroleptic Treatment and Prevalence of Tardive Dyskinesia in Late Life
Sweet et al.
Arch Gen Psychiatry 1995;52:478-486.
ABSTRACT  

Risk Factors for Spontaneous Dyskinesia in Schizophrenia
Fenton et al.
Arch Gen Psychiatry 1994;51:643-650.
ABSTRACT  

Fluoxetine Induced Dyskinesia
Mander et al.
Aust N Z J Psychiatry 1994;28:328-330.
ABSTRACT  

Identifying Risk Factors for Tardive Dyskinesia Among Long-term Outpatients Maintained With Neuroleptic Medications: Results of the Yale Tardive Dyskinesia Study
Morgenstern and Glazer
Arch Gen Psychiatry 1993;50:723-733.
ABSTRACT  

The First Lithium Clinic in Hong Kong: A Chinese Profile
Lee
Aust N Z J Psychiatry 1992;26:450-453.
ABSTRACT  

Dyskinesia and Neuroleptic Exposure in Elderly Psychiatric Inpatients
Sweet et al.
J Geriatr Psychiatry Neurol 1992;5:156-161.
ABSTRACT  

Prospective Study of Tardive Dyskinesia Incidence in the Elderly
Saltz et al.
JAMA 1991;266:2402-2406.
ABSTRACT  

Tardive Dyskinesia in Alzheimer's Disease: Clinical Features and Neuropathologic Correlates
McDaniel et al.
J Geriatr Psychiatry Neurol 1991;4:79-85.
ABSTRACT  

Tardive Dyskinesia in Elderly Psychiatric Patients in Singapore
Tan and Tay
Aust N Z J Psychiatry 1991;25:119-122.
ABSTRACT  

The Prevalence of Tardive Dyskinesia in Neuroleptic-Treated Diabetics: A Controlled Study
Ganzini et al.
Arch Gen Psychiatry 1991;48:259-263.
ABSTRACT  

Is Spontaneous Orofacial Dyskinesia an Artefact Due to Incomplete Drug History?
Ticehurst
J Geriatr Psychiatry Neurol 1990;3:208-211.
ABSTRACT  

ECT and Tardive Dyskinesia
Hay et al.
J Geriatr Psychiatry Neurol 1990;3:106-109.
ABSTRACT  

Tardive Dystonia
Chiu and Lee
Aust N Z J Psychiatry 1989;23:566-570.
ABSTRACT  

Metoclopramide-Induced Movement Disorders: Clinical Findings With a Review of the Literature
Miller and Jankovic
Arch Intern Med 1989;149:2486-2492.
ABSTRACT  

Tardive Dyskinesia in Italy: Preliminary Findings
Muscettola et al.
Arch Gen Psychiatry 1989;46:754-755.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Cognitive Dysfunction, Negative Symptoms, and Tardive Dyskinesia in Schizophrenia: Their Association in Relation to Topography of Involuntary Movements and Criterion of Their Abnormality
Waddington et al.
Arch Gen Psychiatry 1987;44:907-912.
ABSTRACT  

Tardive Dyskinesia and Steady-State Serum Levels of Thiothixene
Yesavage et al.
Arch Gen Psychiatry 1987;44:913-915.
ABSTRACT  

Brain {gamma}-Aminobutyric Acid Abnormality in Tardive Dyskinesia: Reduction in Cerebrospinal Fluid GABA Levels and Therapeutic Response to GABA Agonist Treatment
Thaker et al.
Arch Gen Psychiatry 1987;44:522-529.
ABSTRACT  

Review Article: Psychopharmacologic Treatment in Neurological Practice
Dubovsky and Ringel
Neurorehabil Neural Repair 1987;1:51-66.
 

Tardive Dyskinesia in Young Mentally Retarded Individuals
Gualtieri et al.
Arch Gen Psychiatry 1986;43:335-340.
ABSTRACT  

Penrsistent Tardive Dyskinesia in Bipolar Patients
Mukherjee et al.
Arch Gen Psychiatry 1986;43:342-346.
ABSTRACT  

Duration of Treatment Relationships for Involuntary Movements (Tardive Dyskinesia): Concordance Between Cross-sectional, Clinical, and Longitudinal Animal Studies?
Waddington and Molloy
Arch Gen Psychiatry 1986;43:191-191.
ABSTRACT  

Schizophrenics With Tardive Dyskinesia: Neuropsychological Deficit and Family Psychopathology
Wegner et al.
Arch Gen Psychiatry 1985;42:860-865.
ABSTRACT  

Tardive Dyskinesia in the Aged: Duration of Treatment Relationships
Toenniessen et al.
Arch Gen Psychiatry 1985;42:278-284.
ABSTRACT  

Low-Dose Neuroleptic Treatment of Outpatient Schizophrenics: I. Preliminary Results for Relapse Rates
Kane et al.
Arch Gen Psychiatry 1983;40:893-896.
ABSTRACT  

Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment
Waddington et al.
Science 1983;220:530-532.
ABSTRACT  

Clozapine and Tardive Dyskinesia
Singer
Arch Gen Psychiatry 1983;40:347-347.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.